Name:

Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

ANTIARRHYTHMICS (continued)

GENERIC NAME BRAND NAME(S) CLASS ONSET DURATION DOSAGE RANGE

phenytoin* Dilantin 1B 0.5–1 hr >24 hrs IV: 100–1,000 mg

Oral: 100 mg q6–12h
procainamide Pronestyl IA 0.5 hr >3 hrs Oral: 250–500 mg q3h
Procan SR 6 hrs SR: 250–750 mg q6h
propafenone Rhythmol IC — — 450–900 mg/day
propranolol* Inderal II 0.5 hr 3–5 hrs 10–30 mg 3–4×/day
quinidine Cardioquin IA 0.5 hr 6–8 hrs Oral: 200–600 mg q2–4h
Quinaglute — 8–12 hrs SR: 300–600 mg q8h
Quinidex
sotalol* Betapace III — — 160–640 mg/day
tocainide Tonocard IB 1–2 hrs 8–12 hrs 1,200–1,800 mg/day
verapamil* Calan IV 0.5 hr 6 hrs IV: 5–10 mg
Isoptin
*These agents are also discussed with other classifications.

TOXIC EFFECTS/ADVERSE REACTIONS

Visual disturbances, tinnitus or difficulty hearing, vomiting, constipation or diarrhea, headache, confusion, diaphoresis, angi-
nal attack, rapid rhythm, cardiac arrest. Other signs specific to each drug.

NURSING IMPLICATIONS
General: Use cardiac monitor for intravenous administration and preferably for initiation of oral therapy. Baseline Assessment:
Initial B/P, apical pulse. Intervention/Evaluation: Monitor B/P and apical pulse before giving drug and p.r.n.; notify physician
before administration if B/P or pulse is not within agreed parameters. Assess extremities for edema; weigh daily; check lungs for
rales. Monitor I&O. Check lab results, esp. electrolytes and drug levels. Monitor frequency, consistency of stools; prevent constipa-
tion. Patient/Family Teaching: Teach how to take pulse correctly. Change position slowly to prevent orthostatic hypotension. Do
not take other medications, including OTC, without consulting physician. Restrict sodium and alcohol as ordered.

ANTIBIOTICS
ACTION
Antibiotics (antimicrobial agents) are natural or synthetic compounds that have the ability to kill or suppress the growth of
microorganisms. Narrow-spectrum agents are effective against few microorganisms, whereas broad-spectrum agents are effec-
tive against a wide variety. Antimicrobial agents may also be classified based on their mechanism of action.

1. Agents that inhibit cell wall synthesis or activate enzymes that disrupt cell wall, causing a weakening in the cell wall, cell
lysis, and death. Includes penicillins, cephalosporins, vancomycin, and imidazole antifungal agents.
2. Agents that act directly on cell wall, affecting permeability of cell membranes, causing leakage of intracellular sub-
stances. Includes antifungal agents amphotericin and nystatin, polymixin, and colistin.
3. Agents that bind to ribosomal subunits, altering protein synthesis and eventually causing cell death. Includes aminoglyco-
sides.
4. Agents that affect bacterial ribosome function, altering protein synthesis and causing slow microbial growth. Does not
cause cell death. Includes chloramphenicol, clindamycin, erythromycin, tetracyclines.
5. Agents that inhibit nucleic acid metabolism by binding to nucleic acid or interacting with enzymes necessary for nucleic
acid synthesis. Inhibits DNA or RNA synthesis. Includes rifampin, metronidazole, quinolones (e.g., ciprofloxacin).
6. Agents that inhibit specific metabolic steps necessary for microorganisms, causing a decrease in essential cell compo-
nents or synthesis of nonfunctional analogues of normal metabolites. Includes trimethoprim and sulfonamides.
7. Agents that inhibit viral DNA synthesis by binding to viral enzymes necessary for DNA synthesis, preventing viral replica-
tion. Includes acyclovir, vidarabine.
© 2001 W. B. Saunders Company
SELECTION OF ANTIMICROBIAL AGENTS Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

Goal of therapy is to produce a favorable therapeutic result by achieving antimicrobial action at the site of infection sufficient
to inhibit the growth of the microorganism. The agent selected should be the most active against the most likely infecting
organism, least likely to cause toxicity or allergic reaction. Factors to consider in selection of an antimicrobial agent include:

1. Sensitivity pattern of the infecting microorganism.

2. Location and severity of infection (may determine the route of administration).
3. Pt’s ability to eliminate the drug (status of renal and liver function).
4. Pt’s defense mechanisms (includes both cellular and humoral immunity).
5. Pt’s age, pregnancy, genetic factors, allergy, disorder of CNS, preexisting medical problems.

USES
Treatment of wide range of gram-positive or gram-negative bacterial infections; suppression of intestinal flora before surgery;
control of acne; prophylactically to prevent rheumatic fever; prophylactically in high-risk situations (e.g., some surgical proce-
dures or medical states) to prevent bacterial infection.

PRECAUTIONS
Contraindications: Hypersensitivity to prescribed antibiotics, others in its family, or components of the drug. Some antibiotics
are contraindicated in infants and children (e.g., tetracyclines, quinolones). Extreme Caution: Pregnancy and lactation (avoid
unless benefits clearly outweigh risks). Cautions: Renal or hepatic dysfunction. Elderly and very young may be more sensitive
to effects of these drugs and may require adjusted dosage. Extra care with gastrointestinal diseases and bleeding disorders.

INTERACTIONS
Concurrent use with other antibiotics or drugs that add to or potentiate toxic effects is to be avoided. Alcohol should not be
taken with antibiotics; several may interact with alcohol to produce a disulfiram reaction. Antacids should be administered 2
hrs before or after oral antibiotics to prevent interference with absorption. Refer to specific classification pages or individual
monographs.

SIDE EFFECTS
Side effects most commonly associated with antibiotics are anorexia, nausea, vomiting, and diarrhea. Some, such as tetracy-
clines, produce photosensitivity. Refer to individual monographs.

TOXIC EFFECTS/ADVERSE REACTIONS

Skin rash, seen most often with penicillins and cephalosporins, is a sign of hypersensitivity. Sensitivity reactions may range
from mild rash to anaphylaxis. Superinfections may result from alteration of bacterial environment. Ototoxicity and nephrotox-
icity are potential adverse reactions of a number of antibiotics, esp. the aminoglycosides. Tetracyclines combine with calcium
in forming teeth and may produce discoloration. Severe diarrhea, antibiotic-associated colitis have occurred from several of
the antimicrobials (clindamycin has a particular risk for this reaction).

NURSING IMPLICATIONS
General: Administer drugs on schedule to maintain blood levels. Initiate intravenous solutions slowly with close observation
for sensitivity response. Baseline Assessment: Question for history of previous drug reaction. Culture/sensitivity must be
done before first dose (may give before results are obtained). Assess WBC results, temperature, pulse, respiration. Interven-
tion/Evaluation: Monitor lab results, particularly WBC and culture/sensitivity reports. Assess for adverse reactions.
Patient/Family Teaching: Space doses evenly. Continue therapy for full duration. Avoid alcohol, antacids, or other medica-
tion without consulting physician. Notify physician of diarrhea, rash, or other new symptom.

ANTIBIOTIC: AMINOGLYCOSIDES
ACTION
Bactericidal. Transported across bacterial cell membrane, irreversibly binds to specific receptor proteins of bacterial ribo-
somes. Interferes with protein synthesis, preventing cell reproduction and eventually causing cell death.
© 2001 W. B. Saunders Company
 Name: ROLODEX.WMF
Dimensions: 3096 x 2311 pixels

ANTIBIOTIC: PENICILLINS
ACTION
Penicillins inhibit cell wall synthesis or activate enzymes, which disrupt cell wall, causing a weakening in the cell wall, cell
lysis, and cell death. May be bacteriostatic or bactericidal. Most effective against rapidly dividing cells.

USES
Penicillins may be used to treat a large number of infections including pneumonia and other respiratory diseases, urinary tract
infections, septicemia, meningitis, intra-abdominal infections, gonorrhea and syphilis, bone/joint infection.

PRECAUTIONS
Contraindications: Hypersensitivity to penicillin, cephalosporins, or components. Cautions: Extreme caution with history of
allergies, asthma; gastrointestinal disease; renal dysfunction; bleeding disorders; and (for some penicillins) hepatic dysfunction.

INTERACTIONS
Bacteriostatic antibiotics (e.g., tetracyclines) may decrease bactericidal effects of penicillins. Concurrent use with allopurinol
and ampicillin increases risk of skin rash. Pts should be advised that estrogen contraceptives may have decreased effective-
ness when given with penicillin. Anticoagulants may increase potential for bleeding with high-dose penicillin therapy.
Probenecid increases effects by interfering with excretion.

SIDE EFFECTS
Mild nausea, vomiting, or diarrhea; sore tongue or mouth.

PENICILLINS

GENERIC NAME BRAND NAME(S) RTE ADMIN TYPE DOSAGE RANGE

amoxicillin Amoxil Broad spectrum Oral Adults: 0.75–1.5 g/day

Polymox Children: 20–40 mg/kg/day
Trimox
Wymox
amoxicillin/ Augmentin Broad spectrum Oral Adults: 0.75–1.5 g/day
clavulanate Children: 20–40 mg/kg/day
ampicillin Omnipen Broad spectrum Oral, IM, IV Adults: 1–12 g/day
Polycillin Children: 50–200 mg/kg/day
Principen
ampicillin/ Unasyn Broad spectrum IM, IV Adults: 6–12 g/day
sulbactam
bacampicillin Spectrobid Broad spectrum Oral Adults: 800–1,600 mg/day
Children: 25–50 mg/kg/day
carbenicillin Geocillin Extended spectrum Oral Adults: 382–764 mg 4×/day
cloxacillin Cloxapen Penicillinase resistant Oral Adults: 1–2 g/day
Tegopen Children: 50–100 mg/kg/day
dicloxacillin Dynapen Pencillinase resistant Oral Adults: 1–2 g/day
Pathocil Children: 12.5–25 mg/kg/day
methicillin Staphcillin Penicillinase resistant IM, IV Adults: 4–12 g/day
Children: 100–300 mg/kg/day
mezlocillin Mezlin Extended spectrum IM, IV Adults: 6–18 g/day
Children: 150–300 mg/kg/day
continued
© 2001 W. B. Saunders Company
 Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

PENICILLINS (continued)

GENERIC NAME BRAND NAME(S) RTE ADMIN TYPE DOSAGE RANGE

nafcillin Nafcil Penicillinase resistant Oral, IM, IV Adults (Oral): 1–6 g/day
Unipen Adults (IM, IV): 2–6 g/day
Children (Oral): 25 50 mg/kg/day
Children (IM, IV): 50 mg/kg/day
oxacillin Bactocill Penicillinase resistant Oral, IM, IV Adults (Oral): 2–6 g/day
Prostaphlin Adults (IM, IV): 2–6 g/day
Children (Oral): 50 100 mg/kg/day
Children (IM, IV): 50–100 mg/kg/day
penicillin G Bicillin Natural IM Adults: 1.2 million units/day
benzathine Permapen Children: 0.3–1.2 million units/day
penicillin G Pentids Natural IM, IV Adults: 2–24 million units/day
postassium Pfizerpen Children: 100,000–250,000 units/kg/day
penicillin G Crysticillin Natural IM Adults: 0.6–1.2 million units/day
procaine A.S. Wycillin Children: 0.6–1.2 million units/day
penicillin V Pen-Vee K Natural Oral Adults: 0.5–2 g/day
potassium V-Cillin K Children: 25–50 mg/kg/day
Veetids
piperacillin Pipracil Extended spectrum IM, IV Adults: 6–18 g/day
Children: 200–300 mg/kg/day
piperacillin Zosyn Extended spectrum IV Adults: 3.375 g q6h
tazobactam
ticarcillin Ticar Extended spectrum IM, IV Adults: 12–24 g/day
Children: 50–300 mg/kg/day
ticarcillin Timentin Extended spectrum IM, IV Adults: 3.1 g q4–6h
clavulanate

IM: Intramuscular. IV: Intravenous.

Natural penicillins are very active against gram-positive cocci but ineffective against most strains of Staphylococcus aureus
(inactivated by enzyme penicillinase).
Penicillinase-resistant penicillins are effective against penicillinase-producing Staphylococcus aureus but are less effective
against gram-positive cocci than the natural penicillins.
Broad-spectrum penicillins are effective against gram-positive cocci and some gram-negative bacteria (e.g., Hemophilus
influenzae, Escherichia coli, Proteus mirabilis).
Extended-spectrum penicillins are effective against Pseudomonas aeruginosa, Enterobacter, Proteus species, Klebsiella, and
some other gram-negative microorganisms.

TOXIC EFFECTS/ADVERSE REACTIONS

Hypersensitivity/allergic reactions ranging from skin rashes, urticaria, itching to full anaphylaxis. Superinfections, including
antibiotic-associated colitis. Neurotoxicity, hematologic effects may occur in select drugs.

NURSING IMPLICATIONS
General: Administer drugs on proper schedule to maintain blood levels. Initiate intravenous solutions slowly at first with close
observation for sensitivity response. Baseline Assessment: Question for history of hypersensitivity to penicillin or cephalosporins.
With history of cephalosporin reaction, have emergency equipment, medications available. Culture/sensitivity must be done
before first dose (may give before results are obtained). Assess WBC results, temperature, pulse, respiration. Intervention/Evalua-
tion: Monitor temperature, lab results, particularly WBC and culture/sensitivity reports. Assess for adverse reactions, esp. allergic
reactions, superinfection. Patient/Family Teaching: Space doses evenly. Continue therapy for full duration, usually 7–10 days.
Avoid alcohol, antacids, or other medications without consulting physician. Promptly notify physician of rash or diarrhea.
© 2001 W. B. Saunders Company
 Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

ANTIDEPRESSANTS

GENERIC NAME DOSAGE RANGE

(BRAND NAME) SIDE EFFECTS (MG/DAY)

Monoamine Oxidase Inhibitors

Phenelzine Sedation, hypertensive crisis, weight gain, orthostatic hypotension Oral: 15–90
(Nardil)
Tranylcypromine Sedation, hypertensive crisis, weight gain, orthostatic hypotension Oral: 30–60
(Parnate)

Selective Serotonin Reuptake Inhibitiors

Citalopram Insomnia or sedation, nausea, agitation, headache Oral: 25–60
(Celexa)
Fluoxetine Insomnia or sedation, nausea, agitation, headache Oral: 10–80
(Prozac)
Fluvoxamine Insomnia or sedation, nausea, agitation, headache Oral: 100–300
(Luvox)
Paroxetine Insomnia or sedation, nausea, agitation, headache Oral: 20–50
(Paxil)
Sertraline Insomnia or sedation, nausea, agitation, headache Oral: 50–200
(Zoloft)

Atypical Antidepressants
Bupropion Insomnia, irritability, seizures Oral: 150–450
(Wellbutrin)
Mirtazepine Sedation, dry mouth, weight gain, agranulocytosis, liver toxicity Oral: 15–45
(Remeron)
Nefazodone Sedation, orthostatic hypotension, nausea Oral: 200–600
(Serzone)
Trazodone Sedation, orthostatic hypotension, priapism Oral: 50–600
(Desyrel)
Venlafaxine Increased blood pressure, agitation, sedation, insomnia, nausea Oral: 75–375
(Effexor)

NURSING IMPLICATIONS
General: Closely supervise patients (potential for suicide increases when emerging from depression). Elderly should be
observed carefully for increased response; small doses are usually indicated. Baseline Assessment: Determine initial B/P.
Assess patient and environment for support needed. Intervention/Evaluation: Monitor B/P. Assess mental status. Check
bowel activity; avoid constipation. Patient/Family Teaching: Change positions slowly to avoid orthostatic hypotension. Take
medication as ordered; do not stop taking or increase dosage. Avoid driving or performing tasks that require mental acuity
until response to drug controlled. Extremely important to refrain from alcohol and other medications during therapy and for
2–3 wks thereafter. Omit foods rich in tyramine, such as products containing yeast, beer/wine, aged cheese (list of foods to
avoid should be given); ingestion of such foods and antidepressant may cause hypertensive crisis. Inform other physicians or
dentist of antidepressant therapy. Use protection from sunlight with specific drugs. To the extent possible, drugs that cause
drowsiness should be taken at bedtime, those causing insomnia in the morning.

ANTIDIABETICS
Medications that are currently available in the treatment of diabetes mellitus include insulin, sulfonylureas, alpha-glucosidase
inhibitors, biguanides, meglitinides, and thiazolinediones.

© 2001 W. B. Saunders Company

ACTION Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

Insulin: A hormone synthesized and secreted by beta cells of Langerhans’ islet in the pancreas. Controls storage and utilization
of glucose, amino acids, and fatty acids by activated transport systems/enzymes. Inhibits breakdown of glycogen, fat, protein.
Insulin lowers blood glucose by inhibiting glycogenolysis and gluconeogenesis in liver; stimulates glucose uptake by muscle,
adipose tissue. Activity of insulin is initiated by binding to cell surface receptors.
Sulfonylureas: Stimulate release of insulin from beta cells; increase circulating insulin levels. Bind to specific receptors on
the beta cells when stimulated, allowing influx of calcium through the ATP-sensitive K-channels. Endogenous insulin must be
present for oral hypoglycemics to be effective.
Alpha-glucosidase inhibitors: By inhibiting alpha glucosidase enzymes in small intestine, lower post-prandial blood glucose
by slowing down digestion and absorption of carbohydrates.
Biguanides: Decrease glucose production in the liver, increase glucose uptake into muscle tissues, possibly by increasing
sensitivity of insulin receptors.
Thiazolinediones: Decrease insulin resistance at target tissue; require the presence of insulin.
Meglitinides: Similar acitivity to sulfonylureas, stimulating the release of insulin from beta cells.

USES
Insulin: Treatment of insulin-dependent diabetes (type 1) and noninsulin-dependent diabetes (type 2). Also used in acute situ-
ations such as ketoacidosis, severe infections, major surgery in otherwise noninsulin-dependent diabetics. Administered to pts
receiving parenteral nutrition. Drug of choice during pregnancy.
Sulfonylureas/meglitinides: Control hyperglycemia in type 2 diabetes not controlled by weight and diet alone. Chlor-
propamide also used in adjunctive treatment of neurogenic diabetes insipidus.
Alpha-glucosidase inhibitors: Adjunct to diet to lower blood glucose in pts with noninsulin-dependent diabetes mellitus
(NIDDM) whose hyperglycemia cannot be managed by diet alone.
Biguanides: Adjunct to diet to lower blood glucose in patients with NIDDM whose hyperglycemia cannot be managed by
diet alone.
Thiazolinediones: Adjunct in patients with NIDDM currently on insulin therapy.

INSULIN

HYPOGLYCEMIC EFFECT

BRAND NAME(S) ONSET PEAK (HRS) DURATION (HRS)

Rapid Acting
regular insulin Humulin R 30–60 min 2–4 5–7
Novolin R
insulin lispro Humalog 10–15 min 0.75–1 5

Intermediate Acting
lente insulin Humulin L 1–2.5 hrs 7–15 24
Novolin L
NPH Humulin N 1–1.5 hrs 4–12 24
Novolin N

Long Acting
ultralente Humulin U 4–8 hrs 10–30 >36

PRECAUTIONS
Contraindications: Insulin: Hypersensitivity to animal proteins (human insulin available). Hypoglycemia. Sulfonylureas:
Hypersensitivity to sulfonamides, pregnancy, severe stress or infection, before surgical procedures, in type 1 insulin-dependent
diabetes; hepatic or renal dysfunction; hypoglycemia; lactation. Alpha-glucosidase inhibitors: Hypersensitivity to drug, diabetic
ketoacidosis, cirrhosis, inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, chronic intestinal dis-
ease associated with disorders of digestion or absorption. Biguanides: Renal disease/dysfunction, hypersensitivity to drug,
acute or chronic metabolic acidosis. Caution: Elderly or debilitated patients. Renal or hepatic impairment; alcoholics; car-
diac impairment.

© 2001 W. B. Saunders Company

INTERACTION Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

Insulin: Glucocorticoids, thiazide diuretics may increase blood glucose. Alcohol may increase insulin effect. Beta-adrenergic
blockers may increase risk of hypo/hyperglycemia, mask signs of hypoglycemia, prolong period of hypoglycemia.
Sulfonylureas: May increase effects of oral anticoagulants. Chloramphenicol, MAO inhibitors, salicylates, sulfonamides may
increase effects. Beta blockers may increase hypoglycemic effect, mask signs of hypoglycemia.
Alpha-glucosidase inhibitors: Digestive enzymes, intestinal absorbents (e.g., charcoal) may decrease effect.
Biguanides: Alcohol potentiates effect on lactate metabolism. Cimetidine, furosemide, nifedipine may increase concentra-
tion. Iodinated contrast material may lead to acute renal failure, associated with lactic acidosis.

ORAL ANTIDIABETIC AGENTS

USUAL DAILY DOSAGE

GENERIC NAME BRAND NAME(S) INITIALLY AVERAGE RANGE

Sulfonylureas
acetohexamide Dymelor 250 mg 250–1,500 mg
chlorpropamide Diabinese 100 mg 100–750 mg
glimepiride Amaryl 1–2 mg 1–4 mg
glipizide Glucotrol 2.5–5 mg 2.5–40 mg
glyburide Diabeta 1.25–5mg 1.25–20 mg
Micronase
Glynase
tolazamide Tolinase 100 mg 100–1,000 mg
tolbutamide Orinase 500 mg 500–3,000 mg

Biguanides
metformin Glucophage 500 mg 500–2,550 mg

Alpha glucosidase inhibitors

acarbose Precose 75 mg 150–300 mg
miglitol Glyset 75 mg 75–300 mg

Meglitinide
repaglinide Prandin — 1–16 mg/day

Thiazolinediones
pioglitazone Actos 15–30 mg 15–45 mg
rosiglitazone Avandia 4 mg 4–8 mg

NURSING IMPLICATIONS
General: Administer per schedule; rotate insulin injection sites. Recognize peak action times (see table) as hypoglycemic
reactions may occur at these times. Provide meals on time. Intervention/Evaluation: Monitor blood glucose levels, food
consumption. Check for hypoglycemia: cool, wet skin; tremors; dizziness; headache; anxiety; tachycardia; numbness in
mouth; hunger; diplopia; restlessness, diaphoresis in sleeping pt. Check for hyperglycemia: polyuria, polyphagia, polydipsia,
nausea and vomiting, dim vision, fatigue, deep, rapid breathing. Patient/Family Teaching: Diabetes mellitus requires life-
long control. Prescribed diet is an essential part of treatment; do not skip or delay meals. Weight control, exercise, hygiene
(including foot care), and nonsmoking are integral parts of therapy. Understand significance of illness, stress, and exercise on
regime. Teach how to handle, administer insulin. Carry candy, sugar packets, or other sugar supplements for immediate
response to hypoglycemia. Wear/carry medical alert identification. Avoid alcohol; do not take other medication without con-
sulting physician. Protect skin; limit sun exposure. Select clothing, positions that do not restrict blood flow. Avoid injuries,
exposure to infections. Inform dentist, physician of this medication before any treatment.

© 2001 W. B. Saunders Company

dal symptoms (EPS) may increase with EPS-producing medications. Hypotensives may increase hypotension. May decrease
Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

levodopa effects. Lithium may decrease absorption, produce adverse neurologic effects.

ANTIPSYCHOTICS

SIDE EFFECTS

DOSAGE
GENERIC NAME BRAND NAME(S) SEDATION HYPOTENSION ANTICHOLINERGIC EPS (MG/DAY)

chlorpromazine Thorazine High High Moderate Moderate 30–800

clozapine Clozaril High High High Low 25–900
fluphenazine Prolixin Low Low Low High 0.5–50
haloperidol Haldol Low Low Low High 1–100
loxapine Loxitane Moderate Moderate Low High 20–250
mesoridazine Serentil High Moderate High Low 30–400
molindone Moban Low Low Low High 50–225
olanzapine Zyprexa Moderate Low Moderate Low 5–20
perphenazine Trilafon Low Low Low High 12–64
pimozide Orap Moderate Low Moderate High 1–10
quetiapine Seroquel Moderate Moderate Moderate Low 150–750
risperidone Risperdal Low Low Low Moderate 4–6
thioridazine Mellaril High High High Low 150–800
thiothixene Navane Low Low Low High 6–60
trifluoperazine Stelazine Low Low Low High 4–40

EPS = extrapyramidal symptoms.

SIDE EFFECTS
Orthostatic hypotension, drowsiness, blurred vision, constipation, nasal congestion, photosensitivity.

TOXIC EFFECTS/ADVERSE REACTIONS

Hyperpyrexia, depression, insomnia, convulsions, hypertension, adynamic ileus, laryngospasm, bronchospasm, urticaria, men-
strual irregularities, impotence, urinary retention, blood dyscrasias, systemic lupus-like reaction, extrapyramidal reactions.

NURSING IMPLICATIONS
General: Do not mix parenteral solution with other drugs in the same syringe; give deep intramuscular injections. Have pt
remain recumbent for at least 30 min; following parenteral dose, arise slowly and with assistance. Avoid skin contact with solu-
tions (contact dermatitis). Baseline Assessment: Determine initial B/P, pulse, respirations. Assess pt and environment for
necessary supports. Intervention/Evaluation: Monitor B/P. Assess mental status, response to surroundings. Be alert to suicide
potential as energy increases. Assure that oral medication is swallowed. Check bowel activity; avoid constipation. Promptly
notify physician of extrapyramidal reactions (usually dose related; more frequent in female geriatric pts). Patient/Family
Teaching: Take medication as ordered; do not stop taking or increase dosage. Do not drive or perform activities requiring
motor skills until response has been controlled. Side effects usually subside after approximately 2 wks of therapy or can be
eliminated/minimized by dosage adjustment. Avoid temperature extremes. Avoid alcohol, other medications. Inform other
physicians, dentist of drug therapy. Change positions slowly to prevent orthostatic hypotension.

ANTIVIRALS
Antiviral medications have recently expanded in number due primarily to the increased number of anti-retroviral agents avail-
able for treating patients with HIV infection and its complications. Many of the antivirals are directed toward disrupting one of
the many steps in viral infection and replication. Viruses consist of either a single- or double-stranded DNA or RNA enclosed in
© 2001 W. B. Saunders Company
a protein coat (capsid). Some viruses also have a lipoprotein envelope that may also contain antigenic proteins; other viruses
Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

contain enzymes that initiate viral replication inside a host cell. Viruses reproduce or replicate within cells of the host depend-
ing on metabolic processes of the host cell. They cannot reproduce independent of a host cell because viruses have no meta-
bolic machinery of their own.
Stages of viral replication include cell entry (attachment, penetration); uncoating (release of viral genome); transcription of
viral genome (transcription of viral mRNA, replication of viral genome); translation of viral proteins; post-translational modifica-
tions; assembly of virion components; release (budding). Replication cycle begins when a virion (viral particle) binds to a
receptor site on the plasma membrane of a host cell. Once bound, the virus releases enzymes weakening the plasma mem-
brane, allowing penetration of the virus. Inside the host cell, the outer coat of the virus dissolves releasing viral genetic material
(viral genome), which regulates metabolic activity of the host cell by directing its own replication (synthesis of new messenger
RNA [mRNA]) using host ribosomes and viral proteins. After viral nucleic acids/proteins (virion compound) are assembled to
form a mature virus, it is released from the host cell (budding) for transmission to other host cells, spreading viral infection.
Viruses are DNA or RNA. DNA viruses include herpesvirus (chicken pox, shingles, herpes) and adenoviruses (conjunctivitis,
sore throat). Usually DNA viruses enter the host cell nucleus where viral DNA is transcribed into mRNA of host cell by host cell
mRNA polymerase; mRNA is then translated into virus-specific protein following the usual host cell mechanisms. RNA viruses
include rubella (German measles), orthomyxoviruses (influenza), and paramyxoviruses (measles, mumps). RNA virus replica-
tion in the host cell relies on enzymes in the virion to synthesize its mRNA or on the viral RNA serving as its own mRNA. The
mRNA is then translated into various viral proteins, including RNA polymerase that directs the synthesis of more viral mRNA.
Most RNA viruses do not involve the host cell in viral replication.
One special group of RNA viruses, known as retroviruses, are responsible for diseases such as AIDS and T-cell leukemias.
Retroviruses contain a reverse transcriptase enzyme activity that makes a DNA copy of the viral RNA template. This DNA copy
is then integrated into the host genome and transcribed into both genome RNA and mRNA for translation into viral proteins,
giving rise to new virus particles.

ACTION
Effective antivirals must inhibit virus-specific nucleic acid/protein synthesis. Possible mechanisms of action of antivirals used
for non-HIV infection may include interfering with viral DNA synthesis and viral replication, inactivation of viral DNA poly-
merases, incorporation and termination of the growing viral DNA chain, prevention of release of viral nucleic acid into the
host cell, or interference with viral penetration into cells.
Currently three classes of agents are available for the treatment of HIV infection: nucleoside analogues (reverse transcrip-
tase inhibitors), protease inhibitors, and non-nucleoside reverse transcriptase inhibitors (NNRT).
Nucleoside analogues inhibit viral enzyme reverse transcriptase, reducing replication of cell-included HIV virus.
Protease inhibitors suppress viral replication by inhibiting protease, an enzyme responsible for cleaving viral precursor
polypeptides with mature/infective virions.
NNRT inhibits catalytic reaction of reverse transcriptase that is independent of nucleoside binding.

USES
Treatment of HIV infection. Treatment of CMV retinitis in patients with AIDS, acute herpes zoster (shingles), genital herpes
(recurrent), mucosal and cutaneous herpes simplex virus, chicken pox, and influenza A viral illness.

ANTIVIRALS

GENERIC NAME BRAND NAME(S) LABELED USES

abacavir Ziagen HIV infection

acyclovir Zovirax Parenteral:
Mucosal/cutaneous HSV-1 and HSV-2
Varicella zoster (shingles)
Genital herpes
Herpes simplex encephalitis
Oral:
Genital herpes
Herpes zoster (shingles)
Chicken pox (varicella)
adefovir Preveon HIV infection

© 2001 W. B. Saunders Company

 Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

ANTIVIRALS (continued)

GENERIC NAME BRAND NAME(S) LABELED USES

amantadine Symmetrel Influenza A virus respiratory tract illness

amprenavir Agenerase HIV infection
cidofovir Vistide CMV retinitis in pts with AIDS
delavirdine Rescriptor HIV infection
didanosine Videx HIV infection
efavirenz Sustiva HIV infection
famciclovir Famvir Acute herpes zoster (shingles)
Genital herpes (recurrent)
fomivirsen Vitravene CMV retinitis
foscarnet Foscavir CMV retinitis
HSV infections in immunocompromised pts
ganciclovir Cytovene CMV retinitis, CMV disease
indinavir Crixivan HIV infection
lamivudine Epivir HIV infection
nelfinavir Viracept HIV infection
nevirapine Viramune HIV infection
oseltamivir Tamiflu Influenza A and B virus
penciclovir Denavir Cold sores
ramantadine Flumadine Influenza A virus
ribavirin Virazole Lower respiratory infection in infants, children due to respiratory
syncytial virus (RSV)
ritonavir Norvir HIV infection
saquinavir Invirase HIV infection
stavudine Zerit HIV infection
valacyclovir Valtrex Herpes zoster (shingles)
Genital herpes (recurrent)
zalcitabine Hivid HIV infection
zanamivir Relenza Influenza A and B virus
zidovudine Retrovir HIV infection

PRECAUTIONS
Contraindications: Hypersensitivity to any component of the product.
NOTE: Because of the diversity of the antivirals, refer to individual monographs for further information on cautions, side
effects, adverse/toxic effects, drug interactions, etc.

NURSING IMPLICATIONS
Baseline Assessment: Assess health history (past medical, drug history, lifestyle, type/severity of symptoms). Ask about
fatigue, chills, sweating, skin color changes. Note any localized swelling, pain, tenderness in lymph node regions. Assess for
pregnancy/lactation. Intervention/Evaluation: Monitor renal function, fluid status, I/O, sleep and rest patterns, altered nutri-
tion related to nausea produced by the antivirals. Observe for therapeutic effect, signs/symptoms of improvement. Monitor for
undesired clinical response/toxicity associated with antivirals. Review results assessing renal/hepatic function and integrity of
hemopoietic system. Inspect intravenous infusion site carefully. Patient/Family Teaching: Inform pt of importance of immu-
nization and maintaining immunization against viral infections for small children and adults at high risk of acquiring influenza.
Inform pt of importance of adequate fluid intake. Call physician if condition worsens or pt experiences any toxicity with the
medication. Inform of ways to control spread/recurrence of viral infections. Drug therapy for AIDS/genital herpes does not pre-
vent transmission to others or prevent opportunistic infections.

© 2001 W. B. Saunders Company

 Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

BETA BLOCKERS (continued)

GENERIC NAME BRAND NAME(S) SELECTIVITY USES DOSAGE RANGE

nadolol Corgard Beta1, beta2 HTN, angina HTN: 40–320 mg/day

Angina: 40–240 mg/day
penbutolol Levotol Beta1, beta2 HTN HTN: 10–40 mg/day
pindolol Visken Beta1, beta2 HTN HTN: 10–60 mg/day
propranolol Inderal Beta1, beta2 HTN, angina, arrhythmias, HTN: 120–640 mg/day
MI, migraine, tremors Angina: 80–320 mg/day
Arrhythmias: 10–30 mg 3–4×/day
MI: 180–240 mg/day
sotalol Betapace Beta1, beta2 Arrhythmias Arrhythmias: 160–640 mg/day
timolol Blocadren Beta1, beta2 HTN, MI, migraine, glaucoma HTN: 10–60 mg/day
Timoptic MI: 10 mg 2×/day
Ophth: 1 drop 1–2×/day

HTN = hypertension; MI = myocardial infarction.

SIDE EFFECTS
Postural hypotension, lightheadedness, fatigue, weakness, reflex tachycardia.

TOXIC EFFECTS/ADVERSE REACTIONS

Severe hypotension, nausea and vomiting, bradycardia, heart block, circulatory failure.

NURSING IMPLICATIONS
General: Use cardiac monitor for intravenous administration and preferably for initiation of oral therapy. Baseline Assess-
ment: Initial B/P, apical pulse. Intervention/Evaluation: Monitor B/P and apical pulse before giving drug; notify physician
before administration if B/P or pulse are not within agreed parameters. Assess for CHF (dyspnea, peripheral edema, jugular
venous distension, increased weight, rales in lungs, decreased urine output). Assess extremities for peripheral circulation
(warmth, color, quality of pulses). Patient/Family Teaching: Teach how to take B/P, pulse correctly. Change position slowly
to prevent orthostatic hypotension. Do not take OTC cold medications, nasal decongestants. Restrict sodium and alcohol as
ordered. Do not stop taking drug suddenly. Report chest pain, fatigue, shortness of breath.

BRONCHODILATORS
ACTION
Asthma (reversible airway obstruction) is the most common breathing disorder.
Methylxanthines: Directly relax smooth muscle of bronchial airway, pulmonary blood vessels (relieve bronchospasm,
increase vital capacity). Increase cyclic 3,5-adenosine monophosphate.
Beta2-adrenergic agonists: Stimulate beta receptors in lung, relax bronchial smooth muscle, increase vital capacity, decrease
airway resistance.
Anticholinergics: Inhibit cholinergic receptors on bronchial smooth muscle (block acetylcholine action).
Leukotriene receptor antagonist: Blocks effects of leukotriene (bronchoconstriction, inflammation, edema).
Antileukotriene: Inhibits enzyme 5-lipoxygenase, reducing production of leukotriene, a bronchoconstrictor.

USES
Relief of bronchospasm occurring during anesthesia; in bronchial asthma, bronchitis, or emphysema.

PRECAUTIONS
Contraindications: Hypersensitivity to that agent or intolerance to others in the classification, components of preparation.
Severe renal or hepatic dysfunction. Cautions: Pregnancy, lactation, elderly, hepatic disease, CHF, or other cardiac condi-
tions that would be adversely affected by cardiac stimulation.
© 2001 W. B. Saunders Company
INTERACTIONS Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

Methylxanthines: Glucocorticoids may produce hypernatremia. Phenytoin, primidone, rifampin may increase metabolism.
Beta blockers may decrease effects. Cimetidine, ciprofloxacin, erythromycin, norfloxacin may increase concentration, toxici-
ty. Smoking may decrease concentration.
Beta2-adrenergic agonists: General anesthetics may increase risk of arrhythmias. Tricyclic antidepressants, maprotiline may
increase cardiovascular effects. May have mutually inhibitory effects with beta-adrenergic blockers. May increase risk of
arrhythmias with digoxin.
Anticholinergics: None significant.

BRONCHODILATORS

GENERIC NAME BRAND NAME(S) ROUTE OF ADMINISTRATION TYPE

albuterol Proventil Inhalation Beta2 agonist

Ventolin Oral
aminophylline — Oral Methylxanthine
Intravenous
bitolterol Tornalate Inhalation Beta2 agonist
epinephrine Adrenalin SubQ Beta2 agonist
Intravenous
ipratropium Atrovent Inhalation Anticholinergic
isoetharine Bronkosol Inhalation Beta2 agonist
isoproterenol Isuprel Inhalation Beta2 agonist
levalbuterol Xopenex Inhalation Beta2 agonist
metaproterenol Alupent Inhalation Beta2 agonist
montelukast Singulair Oral Leukotriene receptor antagonist
salmeterol Serevent Inhalation Beta2 agonist
terbutaline Brethine Inhalation Beta2 agonist
Bricanyl Oral
SubQ
theophylline Aerolate Oral Methylxanthine
Slo-Bid
Slo-Phyllin
Theo-24
Theo-Dur
Theolair
Uniphyl
zafirlukast Accolate Oral Leukotriene receptor antagonist
zileuton Zyflo Oral Antileukotriene

SIDE EFFECTS
Nausea, increased pulse rate, nervousness, weakness, trembling, insomnia.

TOXIC EFFECTS/ADVERSE REACTIONS

Tachycardia, irregular heartbeat, headache, nausea and vomiting, severe weakness, increased B/P.

NURSING IMPLICATIONS
General: Administer oral agents on regular schedule. Assist pt in identifying what triggered an acute bronchospasm attack.
Intervention/Evaluation: Monitor arterial blood gases, serum levels for aminophylline, theophylline. Assess lung sounds,
B/P, pulse, respirations. Encourage fluid intake to decrease viscosity of secretions. Patient/Family Teaching: Demonstrate

© 2001 W. B. Saunders Company

correct use of inhalers. Drink 8 or more glasses of fluid/day. Avoid caffeine-containing products, e.g., coffee, tea, colas, choco-
Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

late (cause further CNS stimulation). Do not smoke. Use other medications only after consulting physician. Teach effective
deep breathing and coughing. Notify physician if symptoms are not relieved or worsen. Report adverse reactions.

CALCIUM CHANNEL BLOCKERS

ACTION
Calcium channel blockers inhibit the flow of extracellular Ca+2 ions across cell membrane of cardiac cells, vascular tissue. Cal-
cium channel blockers relax arterial smooth muscle, depress the rate of sinus node pacemaker, slow AV conduction, decrease
heart rate, produce negative inotropic effect (rarely seen clinically due to reflex response). All calcium channel blockers
decrease coronary vascular resistance, increase coronary blood flow, reduce myocardial oxygen demand. Degree of action
varies with individual agent.

CALCIUM CHANNEL BLOCKERS

GENERIC NAME BRAND NAME(S) ONSET ACTION USES RTE ADMIN DOSAGE RANGE

amlodipine Norvasc — Angina Oral 2.5–10 mg/day

Hypertension
bepridil Vascor 1 hr Angina Oral 200–400 mg/day
diltiazem Cardizem 30–60 min Angina Oral, IV Oral: 120–360 mg/day
Cardizem CD Hypertension IV: 20–25 mg
Arrhythmias IV bolus; 5–15 mg/hr
IV infusion
felodipine Plendil 2–5 hrs Hypertension Oral 5–10 mg/day
isradipine DynaCirc 2 hrs Hypertension Oral 5–20 mg/day
nicardipine Cardene 20 min Angina Oral 60–120 mg/day
Hypertension
nifedipine Adalat 20 min Angina SL, Oral Oral: 30–120 mg/day
Procardia Hypertension XL: 30–60 mg/day
nimodipine Nimotop — Subarachnoid Oral 60 mg q4h × 21 days
hemorrhage
nisoldipine Sular — Hypertension Oral 20–60 mg/day
verapamil Calan 30 min Angina Oral, IV Oral: 120–480 mg/day
Isoptin Hypertension
Verelan Arrhythmias IV: 5–10 mg, max: 10 mg/dose

SL: Sublingual. XL: Sustained-release. IV: Intravenous.

USES
Treatment of essential hypertension, treatment and prophylaxis of angina pectoris (including vasospastic, chronic stable,
unstable), prevent/control supraventricular tachyarrhythmias, prevent neurologic damage due to subarachnoid
hemorrhage.

PRECAUTIONS
Contraindications: Renal or hepatic dysfunction, heart block, hypotension, extreme bradycardia, aortic stenosis, sick-sinus
syndrome, severe left ventricular dysfunction, pregnancy, lactation. Cautions: Administer cautiously to elderly because half-
life may be increased. Liver enzymes should be monitored periodically.

INTERACTIONS
Beta-adrenergic blockers may have additive effect. May increase digoxin concentration. Procainamide, quinidine may
increase risk of QT interval prolongation. Carbamazepine, quinidine, theophylline may increase concentration, toxicity.
© 2001 W. B. Saunders Company
 Name: ROLODEX.WMF
Dimensions: 3096 x 2311 pixels

SYMPATHOMIMETICS
ACTION
Sympathetic nervous system (SNS) is involved in maintaining homeostasis (involved in regulation of heart rate, force of car-
diac contractions, B/P, bronchial airway tone, carbohydrate, fatty acid metabolism). The SNS is mediated by neurotransmitters
(primarily norepinephrine, epinephrine, and dopamine), which act on adrenergic receptors. These receptors include beta1,
beta2, alpha1, alpha2, and dopaminergic. Sympathomimetics differ widely in their actions based on their specificity to affect
these receptors. Actions expected by stimulating these receptors include the following:
Alpha1: Mydriasis, constriction of arterioles, veins.
Alpha2: Inhibits transmitter release.
Beta1: Increases rate, force of contraction, conduction velocity of heart, releases renin from kidney.
Beta2: Dilates arterioles, bronchi, relaxes uterus.
Dopamine: Dilates kidney vasculature.

USES
Stimulation of alpha1-receptors: Induces vasoconstriction primarily in skin and mucous membranes; nasal decongestion; com-
bines with local anesthetics to delay anesthetic absorption; increases B/P in certain hypotensive states; produces mydriasis,
facilitating eye exams, ocular surgery.
Stimulation of alpha2-receptors: No therapeutic use.
Stimulation of beta1-receptors: Treatment of cardiac arrest (not primary); treatment of heart failure, shock, AV block (tempo-
rary only).
Stimulation of beta2-receptors: Treatment of asthma; delays premature labor.
Stimulation of dopamine receptors: Treatment of shock.

PRECAUTIONS
Contraindications: Hyperthyroidism, hypertension, cardiovascular disease, narrow-angle glaucoma, Parkinson’s disease, psy-
choneuroses, hypersensitivity. Cautions: Diabetes mellitus, urinary tract obstructions, elderly, debilitated, infants and chil-
dren. See individual monograph for pregnancy, lactation precautions.

SYMPATHOMIMETICS

GENERIC NAME BRAND NAME(S) RECEPTOR SPECIFICITY PRIMARY CLINICAL USE

albuterol Proventil Beta2 Bronchodilator

Ventolin
bitolterol Tornalate Beta2 Bronchodilator
dobutamine Dobutrex Beta1 Inotropic support in pts with cardiac decompensation
Beta2
Alpha1
dopamine Intropin Beta1 Cardiogenic, septic shock
Alpha1 Pressor agent
Dopaminergic
epinephrine Adrenalin Beta1 Allergic reaction
Sus-phrine Beta2 Bronchodilator
Alpha1 Local vasoconstriction
(with anesthetics)
isoetharine Bronkosol Beta2 Bronchodilator
isoproterenol Isuprel Beta1 Heart rate stimulator in bradycardia, heart block
Beta2 Vasopressor in shock
Bronchodilator
metaproterenol Alupent Beta2 Bronchodilator
continued
© 2001 W. B. Saunders Company
 Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

SYMPATHOMIMETICS (continued)

GENERIC NAME BRAND NAME(S) RECEPTOR SPECIFICITY PRIMARY CLINICAL USE

metaraminol Aramine Beta1 Pressor in acute hypotensive states

Alpha1
norepinephrine Levophed Beta1 Pressor in acute hypotensive states
Alpha1
phenylephrine Neo-synephrine Alpha1 Arterial vasoconstrictor
Nasal decongestant
Mydriatic
ritodrine Yutopar Beta2 Arrest premature labor
terbutaline Brethine Beta2 Bronchodilator
Bricanyl

INTERACTIONS
Monoamine oxidase (MAO) inhibitors are contraindicated; in combination with adrenergics, potentiated effects can cause
hypertensive crisis, intracranial hemorrhage, and death. Effects of MAO inhibitors may last 3 wks after discontinuation. General
anesthetics may increase risk of arrhythmias. Tricyclic antidepressants, maprotiline may increase cardiovascular effects. Nor-
epinephrine may decrease effect of methyldopa. May have mutually inhibitory effects with beta-adrenergic blockers. May
increase risk of arrhythmias with digoxin. Ergonovine, oxytocin may increase vasoconstriction. Numerous agents interact with
adrenergics; review each monograph individually.

SIDE EFFECTS
Palpitations, nervousness, restlessness, sweating, difficulty urinating, headache.

TOXIC EFFECTS/ADVERSE REACTIONS

Nausea and vomiting, tachycardia, pale/cold skin, difficulty breathing, significant increase or decrease in B/P. Rare: Chest pain
and irregular heartbeat.

NURSING IMPLICATIONS
General: Immediately obtain intravenous access in cardiac arrest or other emergency. When infusions indicated, pt should be
in intensive care unit with cardiac monitor. Infuse titrate carefully; use infusion pumps for accurate delivery.
Intervention/Evaluation: Monitor vital signs frequently, blood gases, electrolytes, renal and hepatic function results. Assess
multiorgan response. Patient/Family Teaching: Measures to prevent recurrence when given for asthma, COPD such as
avoidance of respiratory infection, prevention of allergen exposure, increased hydration.

THYROID
ACTION
Thyroid hormone (T4 [thyroxine] and T3 [triiodothyroxine]) are essential for normal growth, development, and energy metab-
olism. Promotes growth/development: Controls DNA transcription and protein synthesis. Necessary in development of nervous
system. Stimulates energy use: Increases basal metabolic rate (increases O2 consumption, heat production). Cardiovascular:
Stimulates heart by increased rate, force of contraction, cardiac output.

USES
Treatment of primary or secondary hypothyroidism, myxedema, cretinism, or simple goiter.

© 2001 W. B. Saunders Company

chronic lung conditions. Patient/Family Teaching: Mouthwash, cold drinks, hard candy or gum (if permitted) may be used
Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

for dry mouth. Take safety precautions with drowsiness, blurred vision, or lightheadedness; do not drive or perform activities
requiring mental acuity. Increased fluid intake to decrease viscosity of secretions, aid in bowel elimination. Ophthalmic: Pro-
tect eyes from light; wear sunglasses.

ANTICOAGULANTS/ANTIPLATELETS/THROMBOLYTICS
ACTION
Anticoagulants: Inhibit blood coagulation by preventing the formation of new clots and extension of existing ones. Do not dis-
solve formed clots. Anticoagulants are subdivided into two common classes: Heparin: Directly interferes with blood coagula-
tion by blocking the conversion of prothrombin to thrombin and fibrinogen to fibrin. Coumarin: Acts indirectly to prevent
synthesis in the liver of vitamin K–dependent clotting factors.
Antiplatelets: Interfere with platelet aggregation. Effects are irreversible for life of platelet.
Thrombolytics: Act directly or indirectly on fibrinolytic system to dissolve clots (converting plasminogen to plasmin, an
enzyme that digests fibrin clot).

USES
Anticoagulants: Primarily decrease risk of venous thromboembolism.
Antiplatelets: Primarily decrease risk of arterial thromboembolism.
Thrombolytics: Lyse existing clots.
Treatment and prevention of venous thromboembolism, acute myocardial infarction, acute cerebral embolism; reduces
risk of acute myocardial infarction, total mortality in pts with unstable angina; occlusion of saphenous grafts following open
heart surgery; embolism in select pts with atrial fibrillation, prosthetic heart valves, valvular heart disease, cardiomyopathy.
Heparin also used for acute/chronic consumption coagulopathies (disseminated intravascular coagulation).

PRECAUTIONS
Contraindications: Hypersensitivity, active bleeding, blood dyscrasias and bleeding tendencies, pregnancy. Cautions:
Renal, hepatic dysfunction; alcoholism; history of allergy.

ANTICOAGULANTS/ANTIPLATELETS/THROMBOLYTICS

GENERIC NAME BRAND NAME(S) CLASS DOSAGE RANGE

abciximab ReoPro Antiplatelet Adults: IV bolus: 0.25 mg/kg; IV infusion: 10 mcg/min

alteplase Activase Thrombolytic Adults: IV infusion: 100 mg over 3 hrs (2 hrs for pulmonary
embolism)
anagrelide Agrylin Antiplatelet Adults: Oral: 2–10 mg/day
anistreplase Eminase Thrombolytic Adults: IV push: 30 units over 2–5 min
ardeparin Normiflo Anticoagulant Adults: SubQ: 50 U/kg q12 h
aspirin — Antiplatelet Adults: 81–325 mg/day
clopid rogel Plavix Antiplatelet Adults: Oral: 75 mg once daily
dalteparin Fragmin Anticoagulant Adults: SubQ: 200 IU/kg once daily or 100 IU/kg q12h
danaparoid Organan Anticoagulant Adults: SubQ: 750 units q12h
dipyridamole Persantine Antiplatelet Adults: 75–100 mg 4 times/day
enoxaparin Lovenox Anticoagulant Adults: 30 mg q12h
heparin — Anticoagulant Adults: IV bolus: 5,000 units then IV infusion of 20,000–40,000
units/day
Children: IV bolus: 50 units/kg then IV infusion of 20,000 units/m2/
24 hrs
reteplase Retavase Thrombolytic Adults: IV: 10 units q30min × 2 doses
streptokinase Kabikinase Thrombolytic Adults: (AMI) 1.5 million units over 60 min
Streptase
© 2001 W. B. Saunders Company
 ANTICOAGULANTS/ANTIPLATELETS/THROMBOLYTICS (continued)
Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

GENERIC NAME BRAND NAME(S) CLASS DOSAGE RANGE

ticlopidine Ticlid Antiplatelet Adults: 250 mg 2 times/day

urokinase Abbokinase Thrombolytic Adults: IV: 4,400 IU/kg over 10 min, then 4,400 IU/kg/min for
12–24 hrs
warfarin Coumadin Anticoagulant Adults: Initially, 5–10 mg/day, then 2–10 mg/day

INTERACTIONS
Anticoagulants interact with many drugs and foods. Pts should be cautioned against smoking, alcohol consumption, and use
of OTC drugs. Aspirin, many NSAIDs, antihistamines, diuretics, antibiotics, estrogen contraceptives are among the drugs that
affect anticoagulant action. Any medication taken with an anticoagulant should be checked for interaction. Prothrombin time
(PT) may be shortened by high-fat diet or sudden increase in foods rich in vitamin K. Antidote for heparin: protamine sulfate;
for coumarins: vitamin K.

SIDE EFFECTS
Not common. Local reactions with parenteral administration. Nausea, vomiting, anorexia, and diarrhea with oral administration.

TOXIC EFFECTS/ADVERSE REACTIONS

Minor bleeding to major hemorrhage. Thrombocytopenia and alopecia are transient and reversible. Jaundice, hepatitis,
increased serum transaminase levels with coumarin therapy. Hypersensitivity reactions are rare: fever, chills, urticaria.

NURSING IMPLICATIONS
General: Do not discontinue abruptly. Monitor coagulation test results before administration: for heparin therapy, the activat-
ed partial thromboplastin time (APTT); for coumarin therapy, the PT. Consult physician for targeted coagulation range for indi-
vidual pt (generally, dosage is adjusted to keep results about 1.5–2 times control value for APTT, 1.5 times control value for
PT). Intervention/Evaluation: Assess for bleeding: vital signs, bruises, overt bleeding, and blood in sputum, urine, and feces.
Check for headache, abdominal or back pain. Patient/Family Teaching: Importance of taking drug as directed and periodic
lab tests to determine response to medication. Explain how to check for bleeding signs. Carry identification indicating antico-
agulant therapy. Avoid large quantities of vitamin K–rich food, such as green leafy vegetables, liver, fish, bananas, cauliflower,
tomatoes (decrease effects of oral anticoagulants). Consult physician before taking other medications (including aspirin).
Avoid alcohol. Avoid activities with high risk of injury. Inform physician, dentist of anticoagulant therapy before surgical/den-
tal procedures.

ANTICONVULSANTS
INTRODUCTION
Epilepsy is a condition having a tendency to seizures. Epilepsy is a chronic neurologic disorder that may be the result of brain
injury from difficulties at birth, stroke, head trauma, or brain tumor. However, the majority of cases have no identifiable cause.
The common feature is enhanced susceptibility to recurring seizures caused by abrupt onset of abnormal electrical hyperactiv-
ity in the brain.
Seizures are classified as either partial (beginning in a limited area on one side of the brain) or generalized (beginning on
both sides of the brain). The most common seizure is partial at onset and may become generalized.

ACTION
Anticonvulsants can prevent or reduce excessive discharge of neurons with seizure foci or decrease the spread of excitation
from seizure foci to normal neurons. Exact mechanism unknown but may be due to suppressing sodium influx, suppressing
calcium influx, or increasing the action of GABA, which inhibits neurotransmitters throughout the brain. Anticonvulsants
include the hydantoins, barbiturates, succinimides, oxazolidinediones, benzodiazepines, and several miscellaneous agents
(see table).

© 2001 W. B. Saunders Company

attacks). Do not take alcohol (can cause hypotensive, shocklike state) or other drugs without physician approval. Identify pre-
Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

cipitating factors. Take sublingual tablets sitting or lying down for anginal relief; may repeat every 5 min, up to 3 tablets in 15
min. If no relief, have ambulance transport to hospital. Do not change brands; discard expired drugs. Notify physician of
severe or persistent headache.

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)

ACTION
Exact mechanism for anti-inflammatory, analgesic, antipyretic effects unknown. Inhibition of enzyme cyclooxygenase, the
enzyme responsible for prostaglandin synthesis, appears to be a major mechanism of action. May inhibit other mediators of
inflammation (e.g., leukotrienes). Direct action on hypothalamus heat-regulating center may contribute to antipyretic effect.

NSAIDS

GENERIC NAME BRAND NAME(S) USE: DOSAGE RANGE

aspirin many Aches/pains: 325–650 mg q4h prn

Arthritis: 3.2–6 g/day
Juvenile rheumatoid arthritis: 60–110 mg/kg/day
Acute rheumatic fever: Adults: 5–8 g/day; Children: 100 mg/kg/day
x14 days; then, 75 mg/kg/day ×4–6 wks
Transient ischemic attacks: 1,300 mg/day
Myocardial infarction prophylaxis: 81–325 mg/day
Analgesic/antipyretic (children): up to 60–80 mg/kg/day or 10–15 mg/
kg/dose q4h
bromfenac Duract Pain: 25 mg q6–8h prn
choline salicylate Arthropan Arthritis/pain/fever: 870 mg (5 ml) q3–4h up to 6×/day
diclofenac Voltaren Arthritis: 100–200 mg/day
diflunisal Dolobid Arthritis: 0.5–1 g/day
Pain: 1 g, then 0.5 g q8–12h
etodolac Lodine Arthritis: 600–800 mg/day
Pain: 200–400 mg q6–8h; max: 1200 mg/day
fenoprofen Nalfon Arthritis: 300–600 mg 3–4×/day
Pain: 200 mg q4–6h prn
flurbiprofen Ansaid Arthritis: 200–300 mg/day
ibuprofen Motrin Arthritis: 1.2–3.2 g/day
Pain: 400 mg q4–6h prn
Fever: 200 mg q4–6h prn
Primary dysmenorrhea: 400 mg q4h prn
Juvenile arthritis: 30–40 mg/kg/day
indomethacin Indocin Arthritis: 50–200 mg/day
Bursitis/tendonitis: 75–150 mg/day
Gouty arthritis: 150 mg/day
ketoprofen Orudis Arthritis: 150–300 mg/day
Pain/primary dysmenorrhea: 25–50 mg q6–8h as needed
ketorolac Toradol Pain: Oral: 10 mg q4–6h prn; max: 40 mg/day; IM/IV: 60–120 mg/day
magnesium salicylate Magan Arthritis/pain/fever: 3.6–4.8 g/day in 3–4 divided doses
meclofenamate Meclomen Arthritis: 200–400 mg/day
Pain: 50 mg q4–6h prn
Primary dysmenorrhea: 100 mg 3×/day
nabumetone Relafen Arthritis: 1–2 g/day

© 2001 W. B. Saunders Company

 Name:
Dimensions:
ROLODEX.WMF
3096 x 2311 pixels

NSAIDS (continued)

GENERIC NAME BRAND NAME(S) USE: DOSAGE RANGE

naproxen Anaprox Arthritis: 250–550 mg/day

Naprosyn Pain/1° dysmenorrhea/bursitis/tendonitis: 500 mg, then 250 mg q6–8h
Juvenile arthritis: 10 mg/kg in 2 divided doses
Gouty arthritis: 750 mg, then 250 mg q8h
oxaprozin Daypro Arthritis: 600–1,800 mg/day
piroxicam Feldene Arthritis: 20 mg/day
sodium salicylate Sodium Salicylate Arthritis/pain/fever: 325–650 mg q4h prn
sulindac Clinoril Arthritis: 300 mg/day
Acute gouty arthritis/painful shoulder: 400 mg/day
tolmetin Tolectin Arthritis: 600–1,800 mg/day
Juvenile arthritis: 15–30 mg/kg/day

1° = primary; prn= as circumstances may require.

USES
Provides symptomatic relief from pain/inflammation in the treatment of musculoskeletal disorders (e.g., rheumatoid arthritis,
osteoarthritis, ankylosing spondylitis); analgesic for low to moderate pain; reduces fever (many agents not suited for
routine/prolonged therapy due to toxicity). By virtue of its action on platelet function, aspirin is used in treatment or prophy-
laxis of diseases associated with hypercoagulability (reduces risk of stroke/heart attack).

PRECAUTIONS
Contraindications: Aspirin sensitivity or allergy to other components; pregnancy; lactation; children <14 yrs of age, gastroin-
testinal disorders. Cautions: Renal or hepatic dysfunctions, cardiac or hypertensive disorders, severe infections, elderly, coag-
ulation defects, otic disease.

INTERACTIONS
Salicylates: Antacids, NSAIDs may increase risk of GI effects (e.g., ulceration). Urinary alkalinizers, antacids increase excretion.
Anticoagulants, heparin, thrombolytics increase risk of bleeding. Large doses may increase insulin, oral hypoglycemic effects.
Valproic acid, platelet aggregation inhibitors may increase risk of bleeding. May increase toxicity of methotrexate, zidovudine.
Ototoxic medications, vancomycin may increase ototoxicity. May decrease effect of probenecid, sulfinpyrazone.
NSAIDs: May increase effects of oral anticoagulants, heparin, thrombolytics. May decrease effect of antihypertensives,
diuretics. Salicylates, aspirin may increase risk of GI side effects, bleeding. Bone marrow depressants may increase risk of
hematologic reactions. May increase methotrexate toxicity. Probenecid may increase concentration.

SIDE EFFECTS
Gastrointestinal upset, dizziness, headache, constipation or diarrhea. Ophthalmic: Burning, stinging on instillation, keratitis,
elevated intraocular pressure.

TOXIC EFFECTS/ADVERSE REACTIONS

Hypersensitivity reactions, including skin rash or urticaria. Renal or hepatic toxicity, bone marrow suppression, bleeding, esp.
of gastrointestinal tract. Tinnitus and hearing disturbances. Reactions vary by individual drug.

NURSING IMPLICATIONS
General: Check for aspirin sensitivity (cross-sensitivity). Administer on schedule to maintain blood levels. Provide rest, posi-
tioning, and other comfort measures for pain relief. Baseline Assessment: Assess pain (type, location, intensity). Check tem-
perature, pulse, respirations. Intervention/Evaluation: Assess pain, therapeutic response (decreased temperature, pain
relief, improved mobility). Patient/Family Teaching: Take with meals or on empty stomach, as indicated by individual drug;
however, all drugs may be taken with food, if necessary, to reduce GI side effects. Avoid alcohol and consult physician about
other medications. Refrain from driving or other activities requiring motor response until certain no dizziness present. Inform
other physicians or dentist of drug therapy.

© 2001 W. B. Saunders Company